Nepsis Inc’s Viking Therapeutics VKTX Stock Holding History

Nepsis Inc’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,376	Closed	-$780K	–	32
2024 Q4	$780K	Sell	19,376 -158,338	-89%	-$9.03M	0.19%	27
2024 Q3	$11.3M	Buy	+177,714	New	+$10.4M	2.67%	22

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nepsis Inc's VKTX Position: Q1 2025 in Review

Nepsis Inc sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 19,376 shares — an estimated $780K sold.

Nepsis Inc first reported a position in VKTX in Q3 2024 and held it in 2 quarters. The position peaked at $11.3M in Q3 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Nepsis Inc reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Nepsis Inc sold 19,376 Viking Therapeutics shares in Q1 2025, an estimated $780K.
Nepsis Inc first reported a position in Viking Therapeutics in Q3 2024 and held it in 2 quarters.
Nepsis Inc's Viking Therapeutics position peaked at $11.3M in Q3 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Nepsis Inc's 13F filing for Q1 2025, filed 15 Apr 2025.